Poor
Needs Revision
Patient Risk:
Moderate
Summary
Several interaction claims in the response are not supported or are overextended beyond the supplied label text (e.g., St. John’s wort, CoQ10, red yeast rice, and multiple adverse-effect claims). While the grapefruit juice interaction increasing atorvastatin concentrations and the association of myopathy/rhabdomyolysis with renal failure are supported, the response does not adequately align with label-supported specifics for many items.
Category Scores
Accurate Statements
Grapefruit and grapefruit juice can increase the levels of Lipitor in the bloodstream.
7.2 Grapefruit Juice: grapefruit juice components inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin (especially with excessive consumption).
Rhabdomyolysis can lead to kidney damage.
5.1 Skeletal Muscle: rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported.
Unsupported Statements
St. John's Wort can increase the metabolism of Lipitor (atorvastatin), leading to reduced blood levels of the medication.
No St. John’s wort interaction is described in the supplied label excerpts.
Reduced blood levels of Lipitor from St. John's Wort may reduce Lipitor's effectiveness in lowering cholesterol levels.
St. John’s wort is not supported in the supplied label, and effectiveness reduction is not explicitly linked to an unsupported claim.
Increased Lipitor levels from grapefruit or grapefruit juice can increase the risk of muscle weakness.
The label excerpt supports increased atorvastatin concentrations with grapefruit juice and describes risk of myopathy (muscle aches/weakness) in the class context, but it does not explicitly connect grapefruit juice–induced level increases to muscle weakness risk.
Increased Lipitor levels from grapefruit or grapefruit juice can increase the risk of liver damage.
The supplied grapefruit juice section only addresses plasma concentration increases; the provided liver dysfunction section does not link grapefruit juice to liver damage.
Increased Lipitor levels from grapefruit or grapefruit juice can increase the risk of kidney problems.
While the label links rhabdomyolysis with acute renal failure, the provided text does not explicitly connect grapefruit juice–induced atorvastatin level increases to kidney problems.
Fenofibrate can increase the risk of muscle damage when taken with Lipitor.
The supplied label excerpt mentions fibric acid derivatives increasing risk of myopathy/rhabdomyolysis, but it does not name fenofibrate specifically.
Combining fenofibrate with Lipitor can increase the risk of rhabdomyolysis.
Same issue: fibric acid derivatives are mentioned, but fenofibrate is not specifically named in the supplied text.
Coenzyme Q10 (CoQ10) can interact with Lipitor, reducing its effectiveness in lowering cholesterol levels.
No CoQ10 interaction is described in the supplied label excerpts.
Red yeast rice can interact with Lipitor, reducing its effectiveness.
No red yeast rice interaction is described in the supplied label excerpts.
Red yeast rice can interact with Lipitor, increasing the risk of side effects.
No red yeast rice interaction is described in the supplied label excerpts.
Common side effects of Lipitor include muscle weakness.
The provided label excerpts do not list muscle weakness as a common adverse effect; they describe myopathy as an occasional effect and risk/clinical presentation within warnings.
Common side effects of Lipitor include liver damage.
The provided excerpts describe liver enzyme abnormalities and contraindications/caution, but do not support “common side effects” phrasing or “liver damage” as a common adverse reaction.
Common side effects of Lipitor include kidney problems.
The provided excerpts describe acute renal failure secondary to rhabdomyolysis in rare cases, but do not support kidney problems as a common adverse effect.
Contradictions
Important Omissions
For grapefruit juice, the label excerpt specifies that increased concentrations occur especially with excessive grapefruit juice consumption (>1.2 liters/day), and the response omits this quantifier.
Importance:
Moderate
The response mentions multiple adverse-effect risks (liver damage, kidney problems) associated with grapefruit juice level increases, but the supplied label excerpts do not support these specific associations; a label-aligned response would limit grapefruit discussion to supported concentration increase and the label’s myopathy warning context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims are unsupported (e.g., St. John’s wort, CoQ10, red yeast rice; liver/kidney risks from grapefruit; fenofibrate specificity). These could mislead about interaction hazards or management. One supported link is grapefruit increasing atorvastatin concentrations and rhabdomyolysis being associated with acute renal failure.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Multiple interaction and adverse-effect claims are not supported by the supplied label excerpts or overstate causality (e.g., St. John’s wort, CoQ10, red yeast rice; linking grapefruit-induced levels to liver/kidney risks; describing common side effects).
Suggested Improvement
Restrict claims to label-supported interactions in the provided text (e.g., grapefruit juice increases atorvastatin concentrations; strong CYP3A4 inhibitors and fibric acid derivatives increase myopathy/rhabdomyolysis risk) and avoid naming unlisted agents or labeling events as “common” when the excerpts do not support that frequency.